Answer
Roflumilast inhibits phosphodiesterase-4 (PDE4), an enzyme that metabolises cyclic AMP in structural and inflammatory cells involved in COPD, increasing intracellular cyclic AMP; roflumilast and its active N-oxide metabolite suppress inflammatory mediator release in laboratory studies.
Sources for this answer
- DAXAS 500 micrograms film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 16Document updated
Sources checked